Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Pfizer Files Countersuit Against Moderna In Patent Litigation Over COVID-19 Vaccine

Pfizer Files Countersuit Against Moderna In Patent Litigation Over COVID-19 Vaccine

-Reuters

byMichael Horton

December 5, 2022

1 minute read

-Reuters

HubSpot Analysts Cut Their Forecasts After Q3 Results

By Lisa Levin

November 9, 2:58 PM

HubSpot Inc (NYSE: HUBS) posted upbeat results for its third quarter. Revenue came in at $557.6 million beating estimates of $534.11 million. The company posted EPS of $1.59 versus estimates of $1.24.

HUBS

Deutsche Bank Maintains Buy on Colgate-Palmolive, Lowers Price Target to $85

By Benzinga Newsdesk

October 17, 10:01 AM

Deutsche Bank analyst Steve Powers maintains Colgate-Palmolive (NYSE:CL) with a Buy and lowers the price target from $87 to $85.

Nio Cuts Delivery Times Again While Tesla Model Y China Buyers Keep Waiting

By Anan Ashraf

April 10, 3:04 AM

NIO Inc (NYSE:NIO) has reportedly cut short the wait time to get its two key models delivered. What…

NIO

UnitedHealth, Humana, ChampionX And This Stock Up 42% YTD: CNBC’s ‘Final Trades’

By Priya Nigam

August 10, 8:35 AM

On CNBC’s "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named UnitedHealth Group Incorporated (NYSE: UNH) and Humana Inc. (NYSE:

CHX

Pfizer Files Countersuit Against Moderna In Patent Litigation Over COVID-19 Vaccine

Related Posts

HubSpot Analysts Cut Their Forecasts After Q3 Results

Deutsche Bank Maintains Buy on Colgate-Palmolive, Lowers Price Target to $85

Nio Cuts Delivery Times Again While Tesla Model Y China Buyers Keep Waiting

UnitedHealth, Humana, ChampionX And This Stock Up 42% YTD: CNBC’s ‘Final Trades’